Testosterone flare after initiation of LHRH could theoretically result in symptomatic progression of prostate cancer, though we do not have a high level of evidence to show that this happens, and thus the role of antiandrogens in preventing these side effects is controversial. Here, GNRH1 is linked to prostate carcinoma.